J Cancer 2022; 13(10):2982-2987. doi:10.7150/jca.74022 This issue
1. Health center Evosmos, Thessaloniki, Greece
2. Department of Food Technology, School of Food Technology and Nutrition, Alexander Technological Educational Institute, Thessaloniki, Greece
3. Radiotherapy Department, ``G. Papageorgiou`` University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
4. Oncology Department, General Hospital of Rhodes, Rhodes, Greece
5. Oncology Department, ``Bioclinic`` Private Hospital, Thessaloniki, Greece
6. Oncology Department, General Hospital of Volos, Greece
7. Oncology Department, ``Interbalkan`` European Medical Center, Thessaloniki, Greece
8. Sana Clinic Group Franken, Department of Cardiology / Pulmonology / Intensive Care / Nephrology, ''Hof'' Clinics, University of Erlangen, Hof, Germany
9. Department of Respiratory & Critical Care Medicine, Changhai Hospital, the Second Military Medical University, Shanghai, China
10. Faculty of Medicine, University of Novi Sad, Institute for Pulmonary Diseases of Vojvodina, Novi Sad, Serbia.
11. Department of Pulmonology, University Hospital Zurich, Rämistrasse 100, 8091, Zurich Switzerland
12. Radiology Department, Democritus University of Thrace, Alexandroupolis, Greece
13. Surgery Department, General Clinic Euromedica, Thessaloniki, Greece
14. 3rd Department of Surgery, ``AHEPA`` University Hospital, Aristotle University of Thessaloniki, Medical School, Thessaloniki, Greece
15. Thoracic Surgery Department, ``AHEPA`` University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
16. Department of Chemical Engineering, Aristotle University of Thessaloniki, Thessaloniki, Greece
17. Oncology Department, University General Hospital of Thessaly, Thessaly, Greece
18. Surgery Department, Genesis Private Clinic, Thessaloniki, Greece
19. Pulmonary Oncology Department, ``Bioclinic`` Private Hospital, Thessaloniki, Greece
Background: There are still diagnostic issues with lung cancer and mediastinum lymphadenopathy. Endobronchial ultrasound (EBUS) is a state of the art equipment for the diagnosis of lymphadenopathy and central lesions.
Objective: To investigate the sample size with one pass.
Patients and Methods: 248 Stage IV patients were included in our study. All patients had a CT of the thorax with either lymphadenopathy or lyphadenopathy plus pulmonary lesions. Patients had a biopsy with endobronchial ultrasound with 22G Mediglope, 22G Mediglope Sonotip, 21G Olympus and 19G Olympus needle. We collected information regarding the cancer type, cell block, tissue, age, sex, lesion size and needle type.
Results: The cancer type diagnosis was associated with the needle diameter. The number of cell-blocks were associated with the lesion size and needle diameter. Slices from the tissue and cell-blocks were again associated with the lesion size and needle diameter.
Conclusion: One pass is enough for cancer diagnosis, however; careful selection has to be made among patients regarding the needle diameter. In the case of lymphoma suspicion we should use 19G needle.
Keywords: lung cancer, biopsy, bronchoscopy, 19G needle, 21G needle, 22G needle, EBUS-TBNA, lymphnodes